Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016

Choose Licence

 

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016 Summary Global Markets Directs, Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016?, provides an overview of the Metastatic Hepatocellular Carcinoma (HCC) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and features dormant and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Hepatocellular Carcinoma (HCC) - The report reviews pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Metastatic Hepatocellular Carcinoma (HCC) therapeutics and enlists all their major and minor projects - The report assesses Metastatic Hepatocellular Carcinoma (HCC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC) Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Metastatic Hepatocellular Carcinoma (HCC) Overview 9 Therapeutics Development 10 Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Overview 10 Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis 11 Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Development by Companies 12 Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Investigation by Universities/Institutes 14 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Products Glance 15 Clinical Stage Products 15 Early Stage Products 16 Metastatic Hepatocellular Carcinoma (HCC) - Products under Development by Companies 17 Metastatic Hepatocellular Carcinoma (HCC) - Products under Investigation by Universities/Institutes 18 Metastatic Hepatocellular Carcinoma (HCC) - Companies Involved in Therapeutics Development 19 Acceleron Pharma, Inc. 19 AstraZeneca Plc 20 AVEO Pharmaceuticals, Inc. 21 Celgene Corporation 22 Eisai Co., Ltd. 23 Eli Lilly and Company 24 F. Hoffmann-La Roche Ltd. 25 HanAll Biopharma Co., Ltd. 26 Johnson & Johnson 27 Millennium Pharmaceuticals Inc 28 Mirna Therapeutics, Inc. 29 Molecular Partners AG 30 MolMed S.p.A. 31 Novartis AG 32 OncoMed Pharmaceuticals, Inc. 33 Pfizer Inc. 34 PharmAbcine, Inc. 35 Verlyx Pharma Inc. 36 Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Target 38 Assessment by Mechanism of Action 41 Assessment by Route of Administration 44 Assessment by Molecule Type 46 Drug Profiles 48 AV-203 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 AZD-9150 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 CC-122 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Cellular Immunotherapy for Metastatic Hepatocellular Carcinoma - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 codrituzumab - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 crizotinib - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 dalantercept - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 emibetuzumab - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 erdafitinib - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 golvatinib tartrate - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 HL-143 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 ipafricept - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 LY-3039478 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 LY-3127804 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 MP-0250 - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 MRX-34 - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 NGR-hTNF - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 OSU-2S - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 palbociclib - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 pasireotide - Drug Profile 106 Product Description 106 Mechanism Of Action 106 R&D Progress 106 pentamidine isethionate - Drug Profile 110 Product Description 110 Mechanism Of Action 110 R&D Progress 110 PF-04518600 - Drug Profile 112 Product Description 112 Mechanism Of Action 112 R&D Progress 112 PTX-9908 - Drug Profile 113 Product Description 113 Mechanism Of Action 113 R&D Progress 113 sapanisertib - Drug Profile 114 Product Description 114 Mechanism Of Action 114 R&D Progress 114 sonidegib phosphate - Drug Profile 117 Product Description 117 Mechanism Of Action 117 R&D Progress 117 temsirolimus - Drug Profile 122 Product Description 122 Mechanism Of Action 122 R&D Progress 122 TTAC-0001 - Drug Profile 124 Product Description 124 Mechanism Of Action 124 R&D Progress 124 utomilumab - Drug Profile 125 Product Description 125 Mechanism Of Action 125 R&D Progress 125 Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects 127 Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products 128 Metastatic Hepatocellular Carcinoma (HCC) - Product Development Milestones 129 Featured News & Press Releases 129 Jul 30, 2013: Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio 129 May 13, 2013: Marina Biotech's Licensee Mirna Therapeutics Initiates Phase I Clinical Trial Of Anticancer Drug MRX34 129 Appendix 130 Methodology 130 Coverage 130 Secondary Research 130 Primary Research 130 Expert Panel Validation 130 Contact Us 130 Disclaimer 131

List of Tables Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H2 2016 10 Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Comparative Analysis by Clinical Stage Development, H2 2016 15 Comparative Analysis by Early Stage Development, H2 2016 16 Products under Development by Companies, H2 2016 17 Products under Investigation by Universities/Institutes, H2 2016 18 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Acceleron Pharma, Inc., H2 2016 19 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AstraZeneca Plc, H2 2016 20 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 21 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Celgene Corporation, H2 2016 22 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Eisai Co., Ltd., H2 2016 23 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Eli Lilly and Company, H2 2016 24 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 25 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 26 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Johnson & Johnson, H2 2016 27 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 28 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Mirna Therapeutics, Inc., H2 2016 29 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Molecular Partners AG, H2 2016 30 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by MolMed S.p.A., H2 2016 31 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Novartis AG, H2 2016 32 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016 33 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Pfizer Inc., H2 2016 34 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by PharmAbcine, Inc., H2 2016 35 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Verlyx Pharma Inc., H2 2016 36 Assessment by Monotherapy Products, H2 2016 37 Number of Products by Stage and Target, H2 2016 39 Number of Products by Stage and Mechanism of Action, H2 2016 42 Number of Products by Stage and Route of Administration, H2 2016 45 Number of Products by Stage and Molecule Type, H2 2016 47 Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects, H2 2016 127 Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products, H2 2016 128


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Global Markets Direct

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017 Summary Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining b...

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017 Summary According to the recently published report 'Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017'; Transthyretin (ATTR or Prealbumin or TBP...

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017 Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein...

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017 Summary Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. Out of which approximat...

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary According to the re...

New Pharmaceuticals and Healthcare Reports